Smac Mimetics Combined with Innate Immune Stimuli Create the Perfect Cytokine Storm to Kill Tumor Cells
Overview
Affiliations
A dual immunotherapy approach employing small-molecule inhibitors of apoptosis (IAP) protein antagonists in combination with innate immune stimuli has proven to be highly synergistic and effective in animal tumor models. This strategy overcomes many of the limitations of either single agent therapy and our results suggest that the combination could be easily and effectively translated to the clinic.
Binder P, Hashim Y, Cripe J, Buchanan T, Zamorano A, Vangveravong S BMC Cancer. 2022; 22(1):263.
PMID: 35279106 PMC: 8918278. DOI: 10.1186/s12885-022-09367-w.
Targeting triple-negative breast cancers with the Smac-mimetic birinapant.
Lalaoui N, Merino D, Giner G, Vaillant F, Chau D, Liu L Cell Death Differ. 2020; 27(10):2768-2780.
PMID: 32341449 PMC: 7492458. DOI: 10.1038/s41418-020-0541-0.
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Hofmann M, Mani R, Engelhardt H, Impagnatiello M, Carotta S, Kerenyi M Mol Cancer Ther. 2020; 19(4):1018-1030.
PMID: 32024684 PMC: 7661742. DOI: 10.1158/1535-7163.MCT-19-0789.
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy.
Michie J, Kearney C, Hawkins E, Silke J, Oliaro J Cells. 2020; 9(1).
PMID: 31947615 PMC: 7017284. DOI: 10.3390/cells9010207.
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Zhou L, Zhang Y, Leng Y, Dai Y, Kmieciak M, Kramer L J Hematol Oncol. 2019; 12(1):25.
PMID: 30845975 PMC: 6407248. DOI: 10.1186/s13045-019-0713-x.